Search Follow us

Transgene (TNG)

Business description

Transgene is a French company developing immunotherapy agents for cancer and infectious diseases. Oncolytic virus Pexa-Vec (Phase III for HCC) and cancer vaccine TG4010 (Phase II for NSCLC) are the lead clinical candidates.

Potential confirmed but checkpoint data needed

Update | Pharmaceutical & healthcare | 03/06/2015

The therapeutic potential of Transgene’s TG4010 in non-squamous non-small cell lung cancer (NSCLC) was supported by the more mature overall survival (OS) Phase IIb data. However, we expect that additional data from combination studies with checkpoint inhibitors will be required for TG4010 to be out-licensed; these trials should start in H215. Transgene is also planning to initiate a Phase I study with TG1050 for chronic HBV infection. We maintain our valuation at €464m.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€189.3m
Last close€3.040
High / Low (52 weeks)€3.5 / €2.5
Stock market listingEU
Forecast net debt (€m)45.2
Forecast gearing ratio (%)1863
SectorPharmaceutical & healthcare

Price performance

Relative *(2.8)6.6(11.7)

* % Relative to local index

Company news